According to FibroAction, a major trial of the drug Reboxetine for Fibromyalgia Syndrome (Fibro) is currently recruiting patients in the USA and Canada.
The 14 week randomised double-blind Phase III trial, sponsored by Pfizer, will recruit around 1150 Fibro patients in 120 locations across the USA and Canada. Pfizer estimate that the trial will be completed in April 2009.
For more information, see the FibroAction article.
FibroAction is a new organisation, basd in the UK, which aims to make accurate, up-to-date information about Fibromyalgia Syndrome (Fibro) readily available, as well as raise awareness of the condition.
September 26, 2008 at 11:01 pm
I think that I should be a part of your study. I
wld like to know how I can
qualify for your study
October 15, 2008 at 3:47 am
I believe I am a good fit for this NE study. How might I discuss this further?
October 16, 2008 at 5:57 am
Please contact Pfizer about the trial. FibroAction only publicised the news – we are not organising the trial itself.